



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| (51) International Patent Classification⁴ : A01N 25/28, A61K 9/52, 9/50 | A1 | (11) International Publication Number: WO 88/ 09121 (43) International Publication Date: 1 December 1988 (01.12.88) |
| (21) International Application Number: PCT/AU88/00157 (22) International Filing Date: 24 May 1988 (24.05.88) (31) Priority Application Number: PI 2220 (32) Priority Date: 29 May 1987 (29.05.87) (33) Priority Country: AU (71) Applicant (for JP only): ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED [AU/AU]; 1 Nicholson Street, Melbourne, VIC 3001 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only) : TRAU, Matt [AU/AU]; 81 Union Street, Northcote, VIC 3070 (AU). TRUSS, Rowan, W. [AU/AU]; 22 Devereaux Street, Oak Park, VIC 3046 (AU). (74) Agent: DAVY, John, R.; Industrial Property Section, ICI Australia Operations Proprietary Limited, 1 Nicholson Street, P.O. Box 4311, Melbourne, VIC 3001 (AU). | | (81) Designated States: JP, US. Published <i>With international search report.</i> |
| (54) Title: CONTROLLED RELEASE POLYMER MICROSPHERES (57) Abstract <p>Controlled release microspheres of hydroxybutyrate polymer comprise active ingredient and hydroxybutyrate/hydrovalerate copolymer. The microspheres comprise a skin which is distinct from the general bulk of the microspheres, and this skin may have a porosity covering from 0-50 % of the total surface area of the microsphere, this porosity being largely controlled by varying the hydroxyvalerate content of the polymer. The porosity of the interior of the microspheres can also be regulated. Control of the two porosities permits the attainment of a wide range of release rates for a wide range of active ingredients. The microspheres can be used in a wide variety of pharmaceutical, veterinary and agricultural applications.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria | FI | Finland | ML | Mali |
| AU | Australia | FR | France | MR | Mauritania |
| BB | Barbados | GA | Gabon | MW | Malawi |
| BE | Belgium | GB | United Kingdom | NL | Netherlands |
| BF | Burkina Fasso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IT | Italy | RO | Romania |
| BJ | Benin | JP | Japan | SD | Sudan |
| BR | Brazil | KP | Democratic People's Republic of Korea | SE | Sweden |
| CF | Central African Republic | KR | Republic of Korea | SN | Senegal |
| CG | Congo | LJ | Liechtenstein | SU | Soviet Union |
| CH | Switzerland | LK | Sri Lanka | TD | Chad |
| CM | Cameroon | LU | Luxembourg | TG | Togo |
| DE | Germany, Federal Republic of | MC | Monaco | US | United States of America |
| DK | Denmark | MG | Madagascar | | |
| ES | Spain | | | | |

- 1 -

CONTROLLED RELEASE POLYMER MICROSPHERES

This invention relates to the microencapsulation of active substances and to
5 microspheres thus prepared.

The microencapsulation of active substances, that is, substances which have a chemical or biological effect in a suitable environment, is a technique which is well known to the art. Typical
10 examples of active substances which have been encapsulated are drugs and fungicides. The possible reasons for microencapsulation are numerous, for example, to permit the administration of an active substance which could not otherwise be administered,
15 to preserve the active substance in a hostile environment until it can be released in the correct environment, or to extend the release of an active substance over a period of time so as to extend correspondingly the effect of the active
20 substance.

- 2 -

The two last-named categories are often described as "controlled release" applications. Controlled release is an especially useful property in fields such as pharmaceuticals where use has been made of gelatin capsules. A more recent development is the use of microspheres, especially those prepared by solvent evaporation. In this case, the active substance and the microsphere-forming material are dissolved or dispersed in a liquid, commonly an organic liquid, which is then dispersed in a liquid in which the organic liquid is immiscible (water is commonly used) and the organic liquid removed by evaporation to leave microspheres.

The procedure is described by Bissery and co-workers in a paper given at the 3rd Exposition-Congress of the International Technology of Pharmacy (Assoc. Pharm. Galénique Ind. 1983), Vol. 3, pp. 233-9. This paper describes the application of the technique to a number of polymers, including poly(α -hydroxybutyrate). This polymer is described in a further publication by Bissery (chapter 4 of "Microspheres and Drug Therapy: Pharmaceutical, Immunological and Medical Aspects", ed. Davis, Illum, McVie and Tomlinson, Elsevier 1984, pp 217-227) in connection with the anticancer agent CCNU.

Bissery has observed that the surface of a poly(β -hydroxybutyrate) (hereinafter referred to as "PHB") microsphere contains many macroscopic surface pores. This undoubtedly contributes to the fact that PHB microspheres release the active substances encapsulated therein very quickly; the release rates given by Bissery in the second

- 3 -

publication referred to hereinabove are very high. However, this speed of release is not suitable for the whole range of active substances and this limits the usefulness of PHB.

5 It has now been found that it is possible to prepare microspheres comprising PHB wherein the release rate may be altered in a predictable manner. There is therefore provided, according to the present invention, controlled release hydroxy-
10 butyrate polymer microspheres comprising at least one active substance, the polymer comprising a copolymer of 3-hydroxybutyric acid and 3-hydroxyvaleric acid, and the microspheres comprising a continuous skin covering the surface thereof.

15 . PHB, sometimes known in the literature as poly(3-hydroxybutyric acid), is a thermoplastic polymer which is accumulated by many organisms. European Patent Specifications 15669 and 46344 describe typical processes for making PHB. The
20 production of hydroxybutyrate/hydroxyvalerate copolymers is described by, for example, Wallen and co-workers in "Environmental Science and Technology" 8 (1974), 576-9.

 It is a special feature of the microspheres
25 of this invention that, in contrast to the microspheres of the known art, they have a skin, that is, a thin surface layer different in structure to that of the bulk of the microspheres. This skin is continuous over essentially the entire surface of
30 the microspheres. It is, however, permissible that it may have pores therein which give rise to openings at the surface of the skin. The skin can in fact vary between essentially completely pore-less and quite highly porous (pore ends
35 covering up to about 50% of the total skin surface area). It is the combination of the nature of the skin and that of the interior of the microsphere and

- 4 -

the susceptibility of these to controllable alteration which give the microspheres of the present invention unique advantages over the known art.

5 The controlled release characteristics of the microspheres according to the present invention can be modified either by controlling the nature of the skin or by controlling the nature of the interior of the microspheres. The nature of the skin may be
10 altered by varying the hydroxyvalerate content of the polymer. This can be done either by varying the hydroxyvalerate content of the copolymer itself or by blending with the copolymer a proportion of PHB homopolymer. It has been observed that as the
15 valerate content rises, the porosity of the skin decreases. At high valerate contents, there is no skin porosity at all, and active ingredients can escape only by diffusion through the polymer matrix.

Other factors such as temperature of
20 evaporation of the solvent, type of solvent and polymer concentration in the organic phase have some effect on skin porosity and thickness, but they exert an effect which is relatively minor in comparison to that produced by hydroxyvalerate
25 content variation.

The interior of the microspheres may be modified in a number of ways, but they all have the common factor of varying the internal porosity of the microspheres. One way of doing this is to add
30 amphipathic material to the copolymer. It has been observed that microspheres produced from the pure copolymer are solid, essentially non-porous spheres. However, the addition of amphipathic material, that is, material having affinity for both phases of a
35 two phase oil/water system, increases the porosity.

- 5 -

The amphipathic material may be, for example, a commercial surfactant or a number of such surfactants. Copolymer from some sources has been found to contain already an amphipathic natural material the nature of which is presently unknown but which can be utilised in place of an addition of amphipathic material. Thus, in order to reduce the porosity in copolymers of this type, the copolymers are purified to the required degree.

10 A further method of modifying the interior is by using a double emulsion technique. This is a well-known technique which involves the stable emulsification of a first liquid in a second liquid with which the first liquid is not compatible, 15 followed by the stable emulsification of the resulting emulsion in a third liquid with which the second liquid is not compatible. Commonly, the first and third liquids are aqueous and the second liquid is a polymer or polymer precursor, such that 20 the end result is a dispersion of polymer microspheres which comprise an inner structure, this generally comprising discrete cells or continuous porosity, depending on the nature of the polymer. In the present invention, the emulsification of an 25 aqueous liquid into a solution of copolymer in a suitable solvent can readily give a desired degree of porosity. The internal aqueous phase may be stabilised by any of the means known to the art, for example, surfactants. It is a feature of some 30 copolymers containing amphipathic natural material of the type described hereinabove that stabilisation of the internal aqueous phase is achieved by this means alone, without further addition of surfactant.

 The active substance for use in this 35 invention can be any suitable active substance. It

- 6 -

can be, for example, a pharmaceutical, a herbicide, an insecticide or a fungicide. Because of the ability (hereinabove described) to alter the surface morphology and therefore the release characteristics of the microspheres according to this invention, an unusually wide range of active substances can be accommodated. It is of course permissible to incorporate more than one active substance in a single microsphere. The active ingredient may be incorporated directly into the copolymer, or in solution or dispersion form. It may be within the cells or pores, the polymer matrix or both.

The microspheres of this invention may be prepared by any means known to the art suitable for the preparation of such microspheres of suitable skin and internal structure. For example, they may be prepared by the solvent evaporation method described in the Bissery publications referred to hereinabove. An alternative method is the double emulsion method hereinabove described. A third method is that described in a copending Australian patent applicant by the same applicant, wherein a copolymer solution is added to a continuous phase which contains the active ingredient.

The invention is further illustrated by the following examples in which all parts are expressed by weight.

Example 1

Preparation of microspheres containing a pesticide.

1 part of a hydroxybutyrate/hydroxy-valerate copolymer (19% valerate content by weight) and 0.25 parts of "Chlorpyrifos" (trade mark) pesticide were dissolved in 30 parts chloroform. This mixture was added to a stirred, heated (55°C) aqueous solution (0.27%) of an 82% hydrolysed grade of polyvinyl

- 7 -

acetate a 4% aqueous solution of which had a viscosity of 9.0 cps at 20°C. The emulsion thus formed was stirred at 250 rpm and maintained at 55°C for 3 hours until the chloroform had completely
5 evaporated. Washing, filtering and drying gave white microspheres of diameter of from 100-500 um.

Examination by scanning electron microscope at magnification x 700 revealed an essentially pore-free skin and sectioned microspheres exhibited
10 a highly porous interior (approximately 40% by volume of spherical pores, the mean pore diameter being about 15 um). X-ray fluorescence revealed the presence of the pesticide within the polymer matrix.

Example 2

15 An example which demonstrates the effect of raising the hydroxyvalerate content of the copolymer.

Example 1 was repeated, with the substitution of an identical quantity of a copolymer containing
20 27% hydroxyvalerate by weight. The interior of the microspheres prepared from this copolymer comprised about 70% by volume of pores with a mean pore size of about 5 um. The skin on the microspheres was essentially pore-free.

25

Example 3

An example which demonstrates the effect of the removal of naturally-occurring amphipathic material.

Example 1 was repeated, with the additional
30 step that the copolymer was purified prior to microsphere manufacture by twice precipitating it from chloroform solution with methanol.

The resultant microspheres were smooth-skinned (no pores) and had a porosity of 15%,
35 the pores being spherical and of mean size 2 um.

- 8 -

The claims defining the invention are as follows:

1. Controlled release hydroxybutyrate polymer microspheres comprising at least one active substance, the hydroxybutyrate polymer comprising a copolymer of 3-hydroxybutyric acid and 3-hydroxyvaleric acid, and the microspheres comprising a continuous skin covering the surface thereof.
2. Controlled release hydroxybutyrate polymer microspheres according to claim 1, wherein the skin comprises pores whose total surface area expressed as a percentage of the total surface area of the microspheres is up to 50% maximum.
3. Controlled release hydroxybutyrate polymer microspheres according to claim 1 or claim 2, wherein the interior of the microspheres beneath the skin comprises porosity.
4. A process of preparing controlled release hydroxybutyrate polymer microspheres according to any one of claims 1 - 3, wherein the surface porosity is selected by the selection of the proportion of hydroxyvalerate content of the hydroxybutyrate polymer.
5. A process according to claim 4, wherein the proportion of hydroxyvalerate in the hydroxybutyrate polymer is altered by altering the proportion thereof in the hydroxyvalerate/hydroxybutyrate copolymer.

- 9 -

6. A process according to claim 4, wherein the proportion of hydroxyvalerate in the hydroxybutyrate polymer is altered by the addition thereto of PHB homopolymer.

7. A process of preparing controlled release hydroxybutyrate polymer microspheres according to claim 3, wherein the porosity of the interior of the microspheres is determined by the inclusion in the polymer of amphipathic material.

8. A process according to claim 7, wherein the amphipathic material comprises at least one surfactant.

9. A process according to claim 7, wherein the porosity is determined by controlling the level of naturally-occurring amphipathic material in the polymer.

10. A process of preparing controlled release hydroxybutyrate polymer microspheres according to claim 3, wherein the porosity of the interior of the microspheres is determined by the use of a double emulsion process.

11. A process of administering an active ingredient at a desired locus by means of controlled release hydroxybutyrate polymer microspheres according to any one of claim 1-3.

12. Controlled release hydroxybutyrate polymer microspheres substantially as described with reference to the examples.

- 10 -

13. A process of preparing controlled release hydroxybutyrate polymer microspheres substantially as described with reference to the examples.

INTERNATIONAL SEARCH REPORT

International Application No PCT/AU88/00157

| I. CLASSIFICATION OF SUBJECT MATTER : (Several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. ⁴ A01N 25/28, A61K 9/52, 9/50 | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|-------------------------------------|---|--|---|--|---|--------|---|---|--------|---|---|--------|---|---|--------|---|---|--------|-----|--|--------|
| II. FIELDS SEARCHED Minimum Documentation Searched ⁷ Classification System Classification Symbols IPC A01N25/28, A61K9/52, 9/50 US Cl. 424-19 Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ AU:IPC as above; Australian Classification 87.18.21 | | | | | | | | | | | | | | | | | | | | | | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1"> <thead> <tr> <th>Category ¹⁰</th> <th>Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th>Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>AU,A, 45677/85 (HOECHST AG) 6 February 1986 (06.02.86)</td> <td>(1-13)</td> </tr> <tr> <td>A</td> <td>US,A, 4491575 (KORSATKO) 1 January 1985 (01.01.85)</td> <td>(1-13)</td> </tr> <tr> <td>A</td> <td>US,A, 4148871 (PITT et al.) 10 April 1979 (10.04.79)</td> <td>(1-13)</td> </tr> <tr> <td>A</td> <td>US,A, 4328204 (WASSERMAN et al.) 4 May 1982 (04.05.82)</td> <td>(1-13)</td> </tr> <tr> <td>A</td> <td>US,A, 4291013 (WAHLIG et al.) 22 September 1981 (22.09.81) See column 3 lines 45-61.</td> <td>(1-13)</td> </tr> <tr> <td>P,A</td> <td>US,A, 4675189 (KENT et al.) 23 June 1987 (23.06.87). See column 12 lines 55-65.</td> <td>(1-13)</td> </tr> </tbody> </table> | | | Category ¹⁰ | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ | A | AU,A, 45677/85 (HOECHST AG) 6 February 1986 (06.02.86) | (1-13) | A | US,A, 4491575 (KORSATKO) 1 January 1985 (01.01.85) | (1-13) | A | US,A, 4148871 (PITT et al.) 10 April 1979 (10.04.79) | (1-13) | A | US,A, 4328204 (WASSERMAN et al.) 4 May 1982 (04.05.82) | (1-13) | A | US,A, 4291013 (WAHLIG et al.) 22 September 1981 (22.09.81) See column 3 lines 45-61. | (1-13) | P,A | US,A, 4675189 (KENT et al.) 23 June 1987 (23.06.87). See column 12 lines 55-65. | (1-13) |
| Category ¹⁰ | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ | | | | | | | | | | | | | | | | | | | | | |
| A | AU,A, 45677/85 (HOECHST AG) 6 February 1986 (06.02.86) | (1-13) | | | | | | | | | | | | | | | | | | | | | |
| A | US,A, 4491575 (KORSATKO) 1 January 1985 (01.01.85) | (1-13) | | | | | | | | | | | | | | | | | | | | | |
| A | US,A, 4148871 (PITT et al.) 10 April 1979 (10.04.79) | (1-13) | | | | | | | | | | | | | | | | | | | | | |
| A | US,A, 4328204 (WASSERMAN et al.) 4 May 1982 (04.05.82) | (1-13) | | | | | | | | | | | | | | | | | | | | | |
| A | US,A, 4291013 (WAHLIG et al.) 22 September 1981 (22.09.81) See column 3 lines 45-61. | (1-13) | | | | | | | | | | | | | | | | | | | | | |
| P,A | US,A, 4675189 (KENT et al.) 23 June 1987 (23.06.87). See column 12 lines 55-65. | (1-13) | | | | | | | | | | | | | | | | | | | | | |
| <p>* Special categories of cited documents: ¹⁴</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> | | | | | | | | | | | | | | | | | | | | | | | |
| IV. CERTIFICATION <table border="1"> <tr> <td>Date of the Actual Completion of the International Search 1 August 1988 (01.08.88)</td> <td>Date of Mailing of this International Search Report (10.08.88) 10 AUGUST 1988</td> </tr> <tr> <td>International Searching Authority Australian Patent Office</td> <td>Signature of Authorized Officer J. BODEGRAVEN</td> </tr> </table> | | | Date of the Actual Completion of the International Search 1 August 1988 (01.08.88) | Date of Mailing of this International Search Report (10.08.88) 10 AUGUST 1988 | International Searching Authority Australian Patent Office | Signature of Authorized Officer J. BODEGRAVEN | | | | | | | | | | | | | | | | | |
| Date of the Actual Completion of the International Search 1 August 1988 (01.08.88) | Date of Mailing of this International Search Report (10.08.88) 10 AUGUST 1988 | | | | | | | | | | | | | | | | | | | | | | |
| International Searching Authority Australian Patent Office | Signature of Authorized Officer J. BODEGRAVEN | | | | | | | | | | | | | | | | | | | | | | |

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 88/00157

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent Document Cited in Search Report | | Patent Family Members | | | |
|--|----|-----------------------|----|----------|-------------|
| AU 45677/85 | DE | 3428372 | DK | 3481/85 | EP 172422 |
| | ES | 545723 | ES | 8608313 | HU 41982 |
| | IL | 75936 | JP | 61043119 | PT 80890 |
| | ZA | 8505769 | | | |
| | | | | | |
| US 4491575 | AT | 3791/82 | AU | 20040/83 | CA 1203480 |
| | EP | 108882 | JP | 59089634 | ZA 8307412 |
| US 4328204 | AU | 33671/78 | CA | 1094450 | DE 2809034 |
| | FR | 2382239 | GB | 1574268 | JP 53109930 |
| | NZ | 186589 | | | |
| | | | | | |
| US 4291013 | AT | 6550/79 | AU | 51556/79 | BE 879252 |
| | CA | 1142433 | CH | 642845 | DE 2843963 |
| | ES | 484821 | ES | 8101886 | FR 2438479 |
| | GB | 2032777 | IL | 58397 | JP 55053214 |
| | NL | 7907450 | SE | 7908313 | US 4347234 |
| | ZA | 7905356 | | | |
| | | | | | |
| | | | | | |
| US 4675189 | AU | 77560/81 | CA | 1176565 | EP 52510 |
| | IL | 64298 | JP | 57118512 | NZ 198982 |
| | PH | 19942 | ZA | 8107973 | |

END OF ANNEX